By admin 
The cornerstone of the administration’s pharmaceutical platform was a highly publicized pledge to make high-priced GLP-1 receptor agonists, such as Wegovy and Zepbound, available to the nation’s lowest-income residents. The logic was rooted in both public health and populism: by treating obesity, the administration argued, the federal government could reduce the long-term costs associated with diabetes, heart disease, and mobility issues. Last year, the White House proposed a novel "negotiation model" where states would bypass traditional pharmacy benefit managers (PBMs) and work directly with the Department of Health and Human Services (HHS) to secure deep discounts from manufacturers like Novo Nordisk and Eli Lilly. In exchange for these lower prices, states were expected to expand their Medicaid formularies to include these weight loss drugs for all eligible beneficiaries.
However, as of late 2026, the data indicates a near-total collapse of this initiative. Only Indiana has formally signed onto the federal negotiation compact, and even there, implementation has been sluggish. Across the rest of the country, the response has ranged from apathy to outright rejection. The primary driver of this failure is the sheer scale of the budgetary impact. Even with a theoretical 50% discount off the list price, the prevalence of obesity among Medicaid populations is so high that covering GLP-1s would threaten to bankrupt state treasuries. In states like Mississippi and West Virginia, where obesity rates frequently exceed 40% of the adult population, the cost of providing $500-a-month injections to hundreds of thousands of beneficiaries would eclipse the spending on all other outpatient medications combined.
Analysis of state budget filings reveals a growing trend of "de-prescribing" or "formulary narrowing." Several states that briefly experimented with weight loss coverage have since revoked it, citing "unsustainable fiscal pressure." These states argue that the federal government’s model failed to account for the "volume cliff"—the phenomenon where the sheer number of eligible patients offsets any per-unit savings achieved through negotiation. Furthermore, the long-term savings promised by the administration remain speculative and years away, while the costs are immediate and compounding. This has created a paradoxical situation where the drugs are theoretically "available" under federal guidance but practically inaccessible to the millions of low-income Americans who were promised a new lease on health.
While the weight loss initiative stalls due to economics, a more profound shift is occurring in the regulatory framework of Medicaid coverage regarding gender-affirming care. The Centers for Medicare and Medicaid Services (CMS) recently finalized a rule, set to take effect on October 13, 2026, that prohibits the use of federal Medicaid and CHIP (Children’s Health Insurance Program) funds for pediatric gender-affirming medications and surgeries. While the administration frames this as a measure to protect minors and ensure "medical prudence," legal experts and healthcare advocates warn that the precedent being set is far broader than a single therapeutic area.
For decades, the Medicaid Drug Rebate Program (MDRP), established in 1990, has operated on a simple "quid pro quo": if a pharmaceutical manufacturer pays a significant rebate to the government, state Medicaid programs are generally required to cover all of that manufacturer’s FDA-approved drugs. There are narrow exceptions for "medical necessity" or specific classes like cosmetic drugs, but the general rule has been one of near-universal access. The new CMS rule challenges this foundation by allowing for "categorical exclusions" based on the type of care rather than the clinical efficacy of the individual drug for an individual patient.
This move has sent shockwaves through the pharmaceutical industry and patient advocacy groups. If the administration can successfully argue that it has the authority to deny federal funding for gender-affirming drugs—despite their FDA approval and the manufacturer’s participation in the rebate program—it effectively grants itself and the states the power to create "closed formularies." Under such a system, Medicaid would look less like a comprehensive entitlement program and more like a private insurance plan where high-cost or politically sensitive treatments can be excluded at will.
Industry analysts suggest that if this legal precedent holds, it could soon be applied to other "budget-busting" categories. The most immediate targets could be ultra-expensive gene therapies for rare diseases, which can cost upwards of $3 million per dose. If a state can exclude gender-affirming care on the grounds of "public interest" or "administrative discretion," they could theoretically apply the same logic to deny a life-saving but fiscally devastating treatment for hemophilia or muscular dystrophy. The STAT report highlights concerns that the "Medicaid mandate" is being dismantled piece by piece, replacing a standardized national benefit with a patchwork of state-by-state exclusions.
The political ramifications are equally significant. The administration’s pivot toward state-led exclusions aligns with a broader "New Federalism" agenda that seeks to shift the burden of healthcare decision-making (and funding) away from Washington. However, this creates a "zip code lottery" for healthcare. A transgender youth in a blue state may still have access to care through state-only funding, while a similar youth in a red state would be entirely cut off. Similarly, the failure of the GLP-1 price deal means that access to obesity treatment is becoming a marker of geographic and political identity rather than clinical need.
Expert perspectives on the matter are sharply divided. Supporters of the administration’s moves argue that the Medicaid program was never intended to be a "blank check" for every new, high-cost therapy that hits the market. They contend that without the ability to exclude certain drugs or negotiate outside the MDRP framework, the entire system will eventually collapse under the weight of innovation. "We are seeing the collision of 21st-century science and 20th-century budgeting," says one healthcare economist. "The current Medicaid structure cannot survive $1,000-a-month weight loss drugs and $3 million-a-dose gene therapies without some form of rationing."
Conversely, civil rights attorneys and medical associations, including the American Medical Association (AMA) and the American Academy of Pediatrics (AAP), argue that the new CMS rule is a dangerous intrusion into the doctor-patient relationship. They assert that the rule ignores established clinical guidelines and uses the Medicaid program as a tool for social engineering. By targeting a marginalized population, they argue, the administration is creating a roadmap for the broader erosion of healthcare rights for all Medicaid beneficiaries.
As the October 13 deadline for the new CMS rule approaches, several states and advocacy groups have already filed lawsuits to block its implementation. These cases are expected to fast-track to the Supreme Court, where the central question will be whether the executive branch has the authority to override the 1990 Medicaid Drug Rebate Act’s coverage requirements. The outcome of this legal battle will determine not just the future of gender-affirming care, but the very nature of the Medicaid promise.
In the interim, the pharmaceutical industry is left in a state of high-stakes uncertainty. Manufacturers who once relied on the "guaranteed market" of Medicaid are now recalculating their R&D and pricing strategies. If Medicaid becomes a program of "selective coverage," the incentive to develop drugs for conditions that primarily affect low-income populations could diminish. The "tirigamisu" of the morning’s Pharmalot column may provide a temporary caffeine boost, but for the millions of Americans navigating the increasingly restricted Medicaid landscape, the long-term prognosis remains clouded by fiscal constraints and a shifting legal paradigm that values state autonomy over universal access. The coming months will reveal whether the Trump administration’s healthcare legacy will be one of "negotiated savings" or a permanent narrowing of the American safety net.
